Fertility
Proov receives MedTech Innovation Briefing from the National Institute for Health Care Excellence
The company is targeting the inclusion of its at-home ovulation test in the NICE guidelines
Proov has announced the publication of a Medtech Innovation Briefing (MIB) on its at-home ovulation test by the UK’s National Institute for Health and Care Excellence (NICE).
NICE is an independent organisation established by the UK Government to provide national guidance and advice to it on medical treatments.
The Medtech Innovation Briefing, known as NICE advice, reports that the technology, if adopted, could result in earlier or more accurate detection of ovulation disorders.
The opinions of four specialist commentators, clinical specialists working in the field, and a patients association were consulted in the development of the MIB.
All experts believed that Proov Confirm, the first and only FDA-cleared test to confirm successful ovulation at home, could replace standard care.
“Proov is very grateful to NICE and the team of expert clinicians for the hard work behind this advice,” said Dr Amy Beckley, CEO of Proov.
“This MIB represents an important milestone in our company’s efforts to facilitate luteal health diagnosis, prevent miscarriage caused by low progesterone and increase pregnancy rates by detecting and addressing suboptimal progesterone levels in early pregnancy.”
Beckley launched Proov after she was diagnosed with unexplained infertility and was recommended IVF.
“I have a PhD in pharmacology, so I’ve been studying hormone signalling for a long time,” she said in an interview with Femtech World.
“I realised the only thing that was different between my IVF cycles and my natural pregnancies was the fact that after embryo transfer I was put on progesterone supplements to support my luteal phase. This matched my previous idea, that I must have a progesterone deficiency causing my short luteal phases.
“Since progesterone in blood fluctuates a lot, one single blood test can’t detect suboptimal levels throughout the implantation window. The research [on progesterone] was there, but nobody had actually come up with a diagnostic test.”
Proov offers a suite of diagnostics to provide fertility insights throughout the entire menstrual cycle by allowing women to measure all of the menstrual hormones daily.
Insight
Covid vaccine not linked to decrease in childbirth, study finds
Insight
Parents sue IVF clinic after delivering someone else’s baby
A Florida couple have sued an IVF clinic after giving birth to a baby who is not genetically related to either of them.
Tiffany Score and Steven Mills hired IVF Life, which operates as the Fertility Center of Orlando in Longwood to help them conceive about five years ago using in vitro fertilisation.
The couple had an embryo implanted in April and welcomed a baby girl nine months later, but soon suspected the clinic had made an error.
Both Score and Mills are white, but the baby had the appearance of a racially non-Caucasian child, according to the lawsuit.
Genetic testing confirmed that the baby is not biologically theirs. The couple filed the lawsuit on 22 January after allegedly trying to contact the clinic multiple times without getting a response.
Jack Scarola, one of the couple’s lawyers, told the Orlando Sentinel: “They have fallen in love with this child. They would be thrilled in the knowledge that they could raise this child.
“But their concern is that this is someone else’s child, and someone could show up at any time and claim the baby and take that baby away from them.”
Score and Mills are also concerned that one of the three fertilised eggs they had frozen at the clinic may have been mistakenly implanted into someone else.
They have demanded that the clinic share what happened with all other patients who had embryos stored at the facility during the year before Score gave birth. They also want IVF Life to pay for genetic testing of every child born as a result of its services over the last five years, and to account for their remaining embryos.
The couple said in a statement: “We love our little girl. We would hope to be able to continue to raise her ourselves with confidence that she won’t be taken away from us.
“At the same time, we are aware that we have a moral obligation to find and notify her biological parents, as it is in her best interest that her genetic parents are provided the option to raise her as their own.”
A family spokesperson said: “Based upon leads discovered to date, and despite the lack of help or cooperation from the clinic, there is hope that we will be able to introduce our daughter to her genetic parents and to find our own genetic child soon.”
The lawsuit names IVF Life LLC and Dr Milton McNichol, who runs the clinic.
The Fertility Center of Orlando had posted a notice on its website stating it is “actively cooperating with an investigation to support one of our patients in determining the source of an error that resulted in the birth of a child who is not genetically related to them.”
The notice was removed after a court hearing on Wednesday.
During the hearing, the judge ordered the clinic to submit a thorough plan for handling the situation by Friday.
McNichol was reprimanded by Florida’s Board of Medicine in May 2024 after an inspection of the clinic in June 2023 revealed several issues, including equipment that did not meet current performance standards, failure to comply with a risk-management plan and missing medication.
He was fined US$5,000.
Fertility
Femtech World Awards to celebrate breakthrough fertility innovations
Fertility innovation is to set to take centre stage at Femtech World’s third annual awards event.
The Femtech World Awards will celebrate some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.
The Fertility Innovation of the Year award celebrates a pioneering product, service or initiative that is transforming fertility care and support.
The winner will have demonstrated exceptional innovation in helping individuals or couples navigate fertility journeys, whether through technology, treatments, education, accessibility, or emotional support.
Consideration will be given to scientific advancement, inclusivity, user impact and the ability to break barriers in fertility health.
The award is sponsored by FinDBest IVF – a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
Launched in 2024, the platform addresses a long-standing challenge in the MedTech sector—fragmented, costly, and inefficient market access—by offering a curated, country-specific directory of active partners, complete with key segmentation, certification indicators, and direct contact tools.
From consumables and lab equipment to AI-powered embryo selection and genetic testing solutions, FinDBest makes it faster and easier for companies to scale internationally—without relying on expensive congresses or cold outreach.
Juan A. Jiménez is founder and CEO of FinDBest IVF.
He said: “As part of its commitment to driving smarter access to reproductive innovation, FinDBest IVF is proudly supporting the Femtech World Fertility Innovation Awards for the second year in a row.
“This collaboration reflects two core beliefs at the heart of the platform.
“First, FinDBest IVF was created to accelerate not only the discovery of innovative fertility solutions but their global adoption.
“By supporting these awards, the platform helps amplify breakthrough technologies—from AI-based egg quality tools to next-gen IVF microdevices—and ensures they can reach the right partners and clinics faster.
“Second, the Awards align with FinDBest’s vision of building a 360-degree commercialisation ecosystem, where innovation is not just recognised, but connected to real-world opportunities.
“Many award nominees are pioneering startups and clinical researchers—exactly the kind of innovators who benefit from FinDBest’s support in navigating regulatory complexity, distributor validation, and go-to-market strategies across diverse regions.
“Together with Femtech World, FinDBest IVF is helping to spotlight, support, and scale the future of fertility care.”
Find out more about the Femtech World Awards and enter for free here.
-
Insight3 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Features3 weeks agoWomen’s health enters a new era – the trends shaping femtech in 2026
-
Features3 weeks agoBest menopause apps and products for 2026
-
Insight1 week agoParents sue IVF clinic after delivering someone else’s baby
-
Ageing4 weeks ago‘Rejuvenated’ eggs raise hopes for improved IVF outcomes
-
Insight2 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight3 weeks agoHigher maternal blood pressure increases risk of pregnancy complications, study finds
-
Entrepreneur4 weeks agoXella Health closes US$3.7 million in pre-seed financing





